Clonmel Healthcare are delighted to announce the introduction of Oyavas®, the new Bevacizumab biosimilar.
Oyavas® is an anti-VEGF monoclonal antibody, indicated for the treatment of the same 6 cancer types as the reference product*†1,2
- Breast cancer
- Cervical cancer
- Colorectal cancer
- Lung cancer
- Ovarian cancer
- Renal cell cancer
Oyavas® is confirmed to be biosimilar to the reference product*3, demonstrated according to EMA recommendations and guidelines.
SIMPLY CONVINCING – with similar efficacy, safety and quality to the reference product*3
Simply AFFORDABLE – with improved cost effectiveness compared to the reference product*4
Simply RELIABLE – with dedicated European production and comprehensive logistical support
Full prescribing information is available on request or alternatively please go to www.clonmel-health.ie. Medicinal product subject to medical prescription.
Please contact Clonmel Healthcare on 01-6204000 or e-mail firstname.lastname@example.org if you require any additional information.
Marketing authorisation number: EU/1/20/1510/001-002. Marketing authorisation holder: STADA Arzneimittel AG, Stadastrasse 2-18, 61118 Bad Vilbel, Germany. Date prepared: July 2021. 2021/ADV/OYA/077H.
† Not all treatment schedules within each cancer type are approved due to patent protection
- Oyavas SmPC (Apr. 2021).
- Avastin SmPC (Feb. 2021)
- Oyavas EPAR Public Assessment Report. Available at: https://www.ema.europa.eu/en/documents/assessment-report/oyavas-epar-public-assessment-report_en.pdf. Last accessed May 2021.
- Cost of Oyavas and reductions in price will vary depending on the market